Jazz Pharmaceuticals

Jazz Pharmaceuticals

Yahoo Finance • 4 days ago

Zymeworks gains following addition to Citi catalyst watch

[Wall Street sign in Lower Manhattan, NYC] georgeclerk * Zymeworks (ZYME [https://seekingalpha.com/symbol/ZYME]) is up ~2% in Monday trading after Citi added the stock to its 90-day catalyst watch list. * The bank sees shares rising d... Full story

Yahoo Finance • 9 days ago

AbCellera Biologics Inc (ABCL) (Q2 2026) Earnings Call Highlights: Strong Pipeline Progress and ...

This article first appeared on GuruFocus. Release Date: August 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points AbCellera Biologics Inc (NASDAQ:ABCL) complete... Full story

Yahoo Finance • 11 days ago

Jazz forecasts $4.60B-$4.75B 2026 revenue as it prepares for Aug. 25 zanidatamab PDUFA

Earnings Call Insights: Jazz Pharmaceuticals (JAZZ) Q2 2026 MANAGEMENT VIEW * Renée Galá (President, CEO & Director) framed the quarter around revenue growth, a guidance raise, and an oncology launch catalyst: "We delivered another out... Full story

Yahoo Finance • 11 days ago

After-Hours Earnings Report for August 3, 2026 : PLTR, VRTX, WMB, OKE, FANG, ON, SBAC, STRL, JAZZ, BWXT, GRAB, TKO

The following companies are expected to report earnings after hours on 08/03/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Palantir Technologies Inc. (PLTR)is reporting for the quarter ending June 30,... Full story

Yahoo Finance • 28 days ago

Stocks Finish Sharply Lower as Tech Stocks Slump

The S&P 500 Index ($SPX) (SPY) on Friday closed down -1.01%, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -0.77%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -1.49%.  September E-mini S&P futures (ESU26) fell -1.02%, a... Full story

Yahoo Finance • 28 days ago

Stocks Pressured by Global Slide in Chipmakers

The S&P 500 Index ($SPX) (SPY) today is down -0.87%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.12%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -1.76%.  September E-mini S&P futures (ESU26) are down -0.87%, and September... Full story

Yahoo Finance • 28 days ago

Stocks Tumble as the Rout in Chipmakers Deepens

The S&P 500 Index ($SPX) (SPY) today is down -1.06%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.12%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -2.23%.  September E-mini S&P futures (ESU26) are down -0.95%, and September... Full story

Yahoo Finance • 28 days ago

Apple upgraded, Brinker initiated: Wall Street's top analyst calls

Apple upgraded, Brinker initiated: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by... Full story

Yahoo Finance • last month

iShares Russell 2000 Value vs. Morningstar Small Cap: Which ETF Suits Your Portfolio Best?

Investors choosing between iShares Morningstar Small Cap Value ETF (NYSEMKT:ISCV) and iShares Russell 2000 Value ETF (NYSEMKT:IWN) must weigh the former's significantly lower expense ratio against the latter's massive liquidity and higher... Full story

Yahoo Finance • 2 months ago

Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?

Just a few days after a well-received initial public offering, a director of drug developer Parabilis Medicines (NASDAQ:PBLS) bought shares in the open market. Director Alan Sebulsky disclosed the purchase of 17,500 shares in multiple ope... Full story

Yahoo Finance • 2 months ago

Weekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera

(RTTNews) - This week, the biotech sector saw FDA approvals, alongside study halts, layoffs, strategic collaborations, acquisitions, deal closures, and encouraging data readouts. Positive clinical readouts spanning therapeutic areas inclu... Full story

Yahoo Finance • 2 months ago

Jazz Pharmaceuticals (JAZZ): Buy, Sell, or Hold Post Q1 Earnings?

Jazz Pharmaceuticals (JAZZ): Buy, Sell, or Hold Post Q1 Earnings? Jazz Pharmaceuticals has had an impressive run over the past six months as its shares have beaten the S&P 500 by 28.7%. The stock now trades at $232.44, marking a 37.1% gai... Full story

Yahoo Finance • 2 months ago

Jazz Pharmaceuticals Phase 3 LAGOON Trial Fails To Meet Primary Endpoint Of Overall Survival

(RTTNews) - Friday, Jazz Pharmaceuticals plc (JAZZ) announced that the Phase 3 LAGOON trial, evaluating Zepzelca (lurbinectedin) in patients with relapsed metastatic small cell lung cancer, did not meet its primary endpoint of overall surv... Full story

Yahoo Finance • 2 months ago

Jazz's Zepzelca Falls Short In Second-Line SCLC Trial

(RTTNews) - Jazz Pharmaceuticals plc (JAZZ) reported top-line results from the Phase 3 LAGOON trial, evaluating Zepzelca (lurbinectedin) in patients with relapsed (second-line) metastatic small cell lung cancer (SCLC). The study, conducte... Full story

Yahoo Finance • 2 months ago

3 Unpopular Stocks We Find Risky

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating bus... Full story

Yahoo Finance • 3 months ago

What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year

Key Points Krensavage bought 241,245 Ultragenyx Pharmaceutical shares last quarter. The quarter-end position value increased by $4.75 million, reflecting both trading and share price changes. The trade represented a roughly 2% increase in... Full story

Yahoo Finance • 3 months ago

3 Healthcare Stocks We Think Twice About

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destocking have persisted in the wake of COVID-19, limiting growth. This has capped... Full story

Yahoo Finance • 3 months ago

3 Mid-Cap Stocks We’re Skeptical Of

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from scaled industry giants and can be disrupte... Full story

Yahoo Finance • 3 months ago

Banking giant massively resets Jazz Pharma stock price target

Changes in Wall Street price targets usually arrive in small increments. A few dollars up, a few dollars down, and sometimes a rating left untouched. UBS skipped that script with Jazz Pharmaceuticals (JAZZ). On May 19, UBS analyst Ashwan... Full story

Yahoo Finance • 3 months ago

JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms

Investing.com -- JPMorgan has reinstated ratings and price targets on 14 large-cap biotechnology companies, describing the sector as being at a critical “inflection point” as pipeline successes increasingly translate into profitable commer... Full story